NASDAQ:TMDX TransMedics Group (TMDX) Stock Price, News & Analysis $70.64 +0.01 (+0.01%) As of 01:38 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About TransMedics Group Stock (NASDAQ:TMDX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TransMedics Group alerts:Sign Up Key Stats Today's Range$69.76▼$71.1850-Day Range$70.74▼$94.7752-Week Range$60.10▼$156.00Volume386,837 shsAverage Volume996,139 shsMarket Capitalization$2.44 billionP/E Ratio18.21Dividend YieldN/APrice Target$115.60Consensus RatingHold Company Overview TransMedics Group, Inc. is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation. TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation. Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets. The company also operates the National OCS Program, which combines its organ-preservation technology with logistical and clinical services to help coordinate organ retrieval, transportation and transplantation. Waleed Hassanein is TransMedics’ president and chief executive officer.AI Generated. May Contain Errors. Read More TransMedics Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreTMDX MarketRank™: 4.58984627309 of 5 starsTransMedics Group scored higher than 92% of companies evaluated by MarketBeat, and ranked 26th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingTransMedics Group has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 5 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialTransMedics Group has a consensus price target of $115.60, representing about 63.8% upside from its current price of $70.57.Amount of Analyst CoverageTransMedics Group has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about TransMedics Group's stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth54.79% Earnings GrowthEarnings for TransMedics Group are expected to grow by 54.79% in the coming year, from $1.46 to $2.26 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TransMedics Group is 18.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.10.Price to Earnings Ratio vs. SectorThe P/E ratio of TransMedics Group is 18.14, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.63.Price to Earnings Growth RatioTransMedics Group has a PEG Ratio of 0.97. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioTransMedics Group has a P/B Ratio of 5.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TransMedics Group's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.25% of the float of TransMedics Group has been sold short.Short Interest Ratio / Days to CoverTransMedics Group has a short interest ratio ("days to cover") of 9.89.Change versus previous monthShort interest in TransMedics Group has recently increased by 2.54%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTransMedics Group does not currently pay a dividend.Dividend GrowthTransMedics Group does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.13 News SentimentTransMedics Group has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for TransMedics Group this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for TMDX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows9 people have added TransMedics Group to their MarketBeat watchlist in the last 30 days. This is an increase of 80% compared to the previous 30 days. Company Ownership3.1 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $109,058.00 in company stock, which represents 0.0045% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, TransMedics Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought $109,058.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders6.90% of the stock of TransMedics Group is held by insiders.Percentage Held by Institutions99.67% of the stock of TransMedics Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TransMedics Group's insider trading history. Receive TMDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TMDX Stock News HeadlinesTransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026October 22, 2026 | prnewswire.comTransMedics Group (NASDAQ:TMDX) & QuidelOrtho (NASDAQ:QDEL) Financial ComparisonOctober 22, 2026 | americanbankingnews.comHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.October 27 at 1:00 AM | Banyan Hill Publishing (Ad)TransMedics Group Inc TMDXOctober 20, 2026 | morningstar.comMTransMedics Group - Some Hiccups In The Long Term Growth StoryOctober 20, 2026 | seekingalpha.comTransMedics Group (TMDX) Stock Looks Undervalued On Current EarningsOctober 17, 2026 | finance.yahoo.comBarclays initiates coverage of TransMedics Group at overweightOctober 8, 2026 | msn.comTransMedics Group consensus price target rises 10.91% to MX$1,984.96October 8, 2026 | msn.comSee More Headlines TMDX Stock Analysis - Frequently Asked Questions How have TMDX shares performed this year? TransMedics Group's stock was trading at $121.65 on January 1st, 2026. Since then, TMDX shares have decreased by 42.0% and is now trading at $70.5680. How were TransMedics Group's earnings last quarter? TransMedics Group, Inc. (NASDAQ:TMDX) posted its quarterly earnings results on Tuesday, August, 4th. The company reported $0.44 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by $0.06. The company's quarterly revenue was up 20.7% on a year-over-year basis. Read the conference call transcript. When did TransMedics Group IPO? TransMedics Group (TMDX) raised $91 million in an IPO on Thursday, May 2nd 2019. The company issued 5,690,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers. Who are TransMedics Group's major shareholders? Top institutional investors of TransMedics Group include Zevenbergen Capital Investments LLC (0.77%), Congress Asset Management Co. (0.73%), Oppenheimer & Co. Inc. (0.31%) and Taylor Frigon Capital Management LLC (0.10%). Insiders that own company stock include James R Tobin, Waleed H Hassanein, Nicholas Corcoran, Miriam Provost, Stephen Gordon, Tamer I Khayal, Thomas J Gunderson, David Weill, Gerardo Hernandez, Anil P Ranganath, Stephanie Lovell and Edward M Basile. View institutional ownership trends. How do I buy shares of TransMedics Group? Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TransMedics Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that TransMedics Group investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Palantir Technologies (PLTR), MercadoLibre (MELI) and Micron Technology (MU). Company Calendar Last Earnings8/04/2026Today10/27/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TMDX's financial health is in the Green zone, according to TradeSmith. TMDX has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:TMDX CIK1756262 Webwww.transmedics.com Phone(978) 552-0900FaxN/AEmployees898Year Founded1998Price Target and Rating Average Price Target for TransMedics Group$115.60 High Price Target$175.00 Low Price Target$77.00 Potential Upside/Downside+63.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)$3.89 Trailing P/E Ratio18.23 Forward P/E Ratio48.57 P/E Growth0.97Net Income$190.29 million Net Margins22.69% Pretax Margin10.85% Return on Equity15.88% Return on Assets5.95% Debt Debt-to-Equity Ratio1.62 Current Ratio6.62 Quick Ratio6.07 Sales & Book Value Annual Sales$605.49 million Price / Sales4.05 Cash Flow$3.94 per share Price / Cash Flow18.01 Book Value$13.79 per share Price / Book5.14Miscellaneous Outstanding Shares34,560,000Free Float32,176,000Market Cap$2.45 billion OptionableOptionable Beta1.94 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:TMDX) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransMedics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransMedics Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
